Introduction
Gram-negative sepsis and endotoxic shock are comcomplication which far outweighs the direct toxicity of the bacterial infection itself in clinical importance.1 plicated pathophysiological entities which have defied effective medical treatment for centuries and Endotoxin, and the SIRS it provokes, are the foci of the development of new antisepsis agents and the are still major sources of morbidity and mortality in the elderly, the immunocompromised, and in the subject of this review. Both Gram-positive organisms such as post-operative setting. Recent studies have estimated a mortality of close to 40% in patients with severe
Staphylococcus aureus and Gram-negative species such as Bordetella pertussis also elaborate proteinsepsis and related haemodynamic compromise.1,2 Past therapeutic research has focused primarily upon aceous exotoxins which appear to act through a similar molecular pathway to that of the much better treating Gram-negative bacteraemia and, in so doing, indirectly blocking the formation and activity of the understood endotoxin;4-6 indeed, a recent study suggested that mortality in Gram-positive septic primary deleterious bacterial product, endotoxin or lipopolysaccharide (LPS) and its associated proinshock may in fact be higher. 7 The clinical and laboratory parameters of Gram-positive and Gramflammatory cytokines (of which tumour necrosis factor alpha and interleukin-1 are probably the most negative infection are not sufficiently different to allow reliable separation by these findings; definitive important). 3 The systemic inflammatory response syndrome (SIRS), or the inflammatory cascade associidentification of the organism by serology or culture of infected fluids or tissue is required.8,9 ated with sepsis and other conditions, is the dreaded With wider understanding of the role of endotoxin include: (i) hypermetabolism, manifested by decreased lipogenesis and increased lipolysis, active in the aetiology of septic shock, the vast majority of research into therapeutics has focused on this bacosteoclastic bone resorption, hyperglycaemia, and fever (due to direct action of TNFa and IL-1b on the terial product rather than the other infection-related toxins. For this reason, this review focuses upon antihypothalamus);12 (ii) coagulopathy, manifested by widespread microvascular endothelial damage secendotoxin therapy specifically and, necessarily, also discusses anti-inflammatory therapy which would ondary to microthrombus formation (due in part to the stimulated secretion of procoagulant mediators theoretically counteract the SIRS associated with all forms of septic shock, regardless of aetiology.
and the direct activation of the extrinsic pathway by TNF);13 (iii) increased vascular permeability due to While the development of new antibiotics directed against the most common aetiological organisms in arachidonic acid metabolites, serotonin, and histamine release;14 (iv) increased leukocyte priming by sepsis has proceeded apace in recent years, the emergence of new pathogens in the nosocomial complement components C3a and C5a for oxygen radical formation, with release of associated collasetting and the increase in antimicrobial resistance among previously susceptible organisms has fregenases and enzymes which contribute further to the vascular compromise and widespread tissue quently produced frustrating treatment failures. As such antimicrobial therapy has often proved unsatisdamage;15,16 (v) systemic vasodilation (with subsequent hypotension) due in part to stimulation of factory in the face of overwhelming sepsis, the direct antagonism of endotoxin and inflammatory cytokines nitric oxide (NO) release by the endothelium of the microvasculature;17 (vi) increased leukocyte adhesin vivo has received much recent attention, and may yet prove the most effective modality in the preveniveness and transmigration with destruction of the microvasculature; and (vii) decrease in the ability of tion and treatment of sepsis and its complications.
the end-organ to utilize oxygen (with an everincreasing reliance on anaerobic metabolism), the mechanism for which is poorly understood.18
Endotoxaemia and the immune
When considering potential approaches to antisepresponse sis therapy, it is important to realize that TNF and the attendant byproducts of the cytokine cascade Sepsis presents in the patient as the consequence of a complex cascade of mediators secreted by immune are, in moderate amounts, beneficial and accelerate recovery from systemic bacterial infection. The miccells in response to the LPS (lipopolysaccharide cell wall, or endotoxin) produced by Gram-negative rovascular changes induced with infection in an immunocompetent individual increase blood flow to infection. Free intravascular LPS is produced from degradation of bacterial cell walls; once in the foci of infection, promote leukocyte adhesion, transmigration, and bactericidal activities, and activate circulation, LPS can bind to a protein, LPS-binding protein (LBP), to form a complex. This complex then the complement cascade to ultimately clear infection.
In addition, the complementary array of endogenous binds with high avidity to a monocyte/macrophage cell surface receptor, CD14, and the result is cellular anti-inflammatory cytokines are simultaneously produced, including IL-4, IL-10, transforming growth activation and secretion of inflammatory cytokines. Similarly, soluble CD14 can also bind LPS/LBP and factor beta, and also specific inhibitors of the cyclooxygenase and coagulation cascades. Ideally, these can thus activate endothelial cells, which do not express surface CD14. 10 factors act in concert with pro-inflammatory mediators to eradicate infection and then return to an Prominent among the mediators produced in response to LPS activation of CD14 is tumour necimmunological steady state. However, when infection is overwhelming or external defenses are conrosis factor (TNF), along with IL-1b and IL-6, eicosanoids, intercellular adhesion molecules, platelet tinuously compromised (e.g. with extensive burns, chronic instrumentation, or immunosuppression), activating factor, oxygen free radicals, and nitric oxide. These primary factors, and many others interpro-inflammatory cytokines may be secreted in abundance, to the point at which the damage to the act with each other and adjacent cells, setting into motion a complex series of local and systemic microvasculature may be irreversible by endogenous counterinflammatory systems. This imbalance inflammatory responses. The secretion of TNF (primarily from macrophages) in particular, is very strongly worsens as the growth of infectious organisms outpaces host immune response and the exogenous stimulated by LPS, and it is believed that this mediator, (and not LPS directly), is one of the primary administration of antibiotics. Ultimately, as immunological 'exhaustion' sets in, the patient suffers agents which sets in motion the exaggerated cellular, metabolic, and vascular responses of septic shock.11
worsening systemic compromise and ultimately, multiorgan system failure and death.19 TNF and its attendant cytokine system exert myriad effects at the cellular and molecular level, which
Other effects of endotoxin in septic shock can further complicate the generalized inflammatory of this document; the reader is directed to several excellent recent reviews on this subject.21-29 state: fever, coagulopathy, decreased haematopoeisis, accelerated metabolism and hyperAs the intricacies of the actions of endotoxin and the related cytokine cascade have become clearer glycaemia, in conjunction with the hyperadrenergic 'stress' state of the patient, all contribute to the in recent years, investigators have turned their attention to specific points in the cascade where antagonexcessive cardiovascular and neurological excitation induced by sepsis, and can accelerate death.
ists, either endogenous or synthetic, could potentially play a role in slowing, stopping, and even reversing Therefore, in addition to the antibiotic treatments specifically directed against the infecting organism, the inflammatory sequelae of sepsis. The septic inflammatory cascade, with potential points of action and the supportive measures of crystalloid fluid resuscitation, colloid infusions, and inotropic/antiof antagonists, is shown in Figure 1 . The following discussion of these points of intervention follows the arrhythmic agents which have been used to control the symptoms of sepsis, much attention has been time-course of events in a 'standard' septic episode. turned in recent research to therapy which is directed against the primary culprit-the endotoxin product Anti-endotoxin therapy itself and the cytokine cascade it invokes.
Lipopolysaccharide (LPS), or endotoxin, is a Gramnegative bacterial product which is localized to, and emanates from, the cell wall of these organisms. This substance is the primary inciting mediator of the
Outlining an effective antisepsis inflammatory response to these organisms in the strategy host, and is composed of three primary components: the O (outer) polysaccharide, the core, and the lipid The treatment of sepsis has traditionally relied upon the management of systemic bacterial infections component (Lipid A).30 These components, while displaying some degree of heterogeneity when comthrough the use of antibiotic therapy directed against the infecting organism. Research concerned with pared across genera and species of bacteria, do share certain homologous sequences which have been anti-endotoxin agents at first focused upon standard antibiotic therapy, in the hopes that any given seized upon as potential targets of therapy, particularly in the lipid A component. Lipid A has in fact antibiotic could act prophylactically to eradicate foci of Gram-negative infection before large amounts of been shown to be the portion of LPS which exerts the toxic effects and incites the inflammatory the endotoxin could be released and thus induce a clinical state of sepsis. This was the rationale behind response of the host.31
The earliest therapeutic investigations involved the preoperative doses of antibiotics before select surgeries, such as colectomy, or universal coverage with administration of polyclonal convalescent sera to septic animals, and later, patients in controlled antibiotics in individuals deemed at greatest risk for septic complications. While this was modestly effectclinical trials.32 Although initial reports using hyperimmune sera were promising, subsequent attempts ive at first, the increasing incidence of multi-drugresistant Gram-negative organisms necessitates to purify a monoclonal antibody (Mab) with broadspectrum reactivity across bacterial genera proved increasingly powerful and expensive regimens, and has diminished the attractiveness of this approach.
daunting. HA-1A (a human Mab) and E5 (a mouse Mab), both with reported specific activity against the In addition, even large doses of antibiotics specific for the infecting organism causing a septic event will
Lipid A region of the endotoxin produced by the J5 strain of Escherichia coli, were shown in multiple have no effect on the already circulating endotoxin, which continues to exert its immunological effects studies to have unsatisfactory binding and neutralizing capability of LPS both in vitro and in vivo,33-35 upon the patient. Further, antibiotic administration to patients unlikely to clear an infection completely and little or no effect on the outcome of Gramnegative sepsis in the clinical setting.36,37 Recentlywith such treatment (e.g. due to insufficient dosing, insufficient spectrum of antibiotic coverage, or partial completed phase III clinical trials with EDOBACOMAB (a murine IgM anti-Lipid A Mab) resistance of organism) may actually worsen the systemic inflammatory response. This paradoxical have demonstrated a similar lack of efficacy, despite encouraging results in animal models.38 Despite such reaction is thought to be secondary to increased endotoxin release with limited bactericidal activity findings, continuing studies with HA-1A in particular have demonstrated recently in a murine model that of the antibiotic and disruption of microbial cell walls containing LPS.20 Although important in the anti-endotoxin antibodies may be of some benefit in specific clinical instances, such as in severe burns therapy of any patient with active infection, a discussion of the current thinking regarding antibiotic and pre-invasive bacterial overgrowth in the gut, to prevent or delay the onset of sepsis.39 Similarly, two therapy in Gram-negative sepsis is beyond the scope clinical trials with E5 did not show improved survival receptor for LPS, and that binding of this ligand to the cell surface initiates part of the cellular cascade in septic shock; however, a meta-analysis combining these trials did demonstrate more rapid recovery and which culminates in sepsis. Extracellular soluble CD14 (sCD14) and a similar agent, LPSimproved survival in a subset of patients who were not in refractory shock at the time of treatment.40 A binding protein, are formed endogenously and thus serve as natural scavengers for excess LPS in the subsequent trial demonstrated no decrease in overall mortality for septic patients who were not yet in circulation and in tissue fluid surrounding foci of infection.44 High serum levels of endogenously proshock, but did show prevention of acute respiratory failure and CNS sequelae of sepsis, and more rapid duced sCD14 in both Gram-negative and Grampositive sepsis have been correlated with a poor resolution of multisystem organ failure in survivors. 41 The efficacy of this agent in sepsis remains controveroutcome,45 implying that this factor must act in accordance with other antimicrobial agents to sial, and further trials are underway. Other monoclonal antibodies under investigation for anti-LPS neutralize LPS, and may not be effective in isolation. The LPS blocking function of sCD14 (i.e. decreased activity include those directed against the outer, or O polysaccharide portion of the molecule;42 others or absent production of IL-8 in presence of LPS) has been demonstrated convincingly in human subjects have proposed development of antibodies specific to the most common organisms producing lipopolyand has been inhibited by mAbs specific for the LPSbinding portion of the molecule.46 Therapeutic saccharide, such as Pseudomonas spp, Klebsiella spp, and others. 43 applications of sCD14 and other LPS-binding proteins are being investigated. Blockade of LPS binding and activation of mononuclear cells offers another potential approach.
An agent homologous to LPS-binding protein, bactericidal/permeability-increasing protein (BPI) is a Immunophenotypic studies of circulating monocytes have demonstrated that CD14 is the membrane naturally occurring compound within the body with natural activity against endotoxin. This highly catfixation of LPS-specific antibodies in these filters has not improved the outcome of this therapy.55 Plasma ionic protein has been isolated in the azurophilic granules of neutrophils and has been shown in vitro exchange procedures to remove such toxins had some success in older studies involving septic neoto bind to several different types of lipopolysaccharide (a negatively charged compound) with high natal dogs and burn patients (as part of multicomponent therapy).56,57 affinity via the lipid A portion of LPS, to prevent neutrophil activation by LPS, and also to inhibit LPSLastly, the phenomenon of induced tolerance to endotoxin and its molecular constituents has been related tumour necrosis factor release both in vitro and in vivo. 47 the subject of some recent study. Research has shown that some animals and human subjects chalRecent research has further identified the specific region of the BPI molecule responsible for its endolenged with LPS will display tolerance (i.e. downregulation of cytokine release) upon rechallenge.58 toxin activity. A 23 kDa fragment (rBPI) was cloned from the N-terminal portion of the molecule, and, Challenge with the purified monophosphoryl lipid A portion of LPS has shown similar effects in a doublewhen expressed, demonstrated anti-endotoxin activity in vitro equal to that of the native product. A blind human trial.59 Investigation into these intriguing findings continues. fusion product incorporating portions of BPI and LPS-binding proteins with affinity for LPS has also been produced.48 Furthermore, a macrophage cell Inhibition of secondary mediators: TNF-a, line, RAW 264.7, with the capability to produce a IL-1, and the cytokine cascade fusion product of BPI and IgG, demonstrated marked resistance to LPS-induced production of TNF and While several agents with specificity for the LPS molecule itself are under investigation, much atten-LPS; infusion of these cell lines or introduction of the transcript via a gene vector may prove effective tion has also been brought to bear on the modulation and arrest of the secondary cascade of cytokines, antisepsis therapy in animal models in the near future.49 coagulation activation, and microvascular compromise which contributes significantly to the morbidity Other substances have shown some specific antiendotoxin activity. Polymyxin B, an antibiotic with and mortality of the primary infective process. Initial attempts at cytokine modulation utilizing corticosaffinity for Lipid A, has been shown to protect mice following a Gram-negative bacterial challenge50 and teroids were disappointing, with an overall increase in mortality;60 currently, systemic corticosteroids are has been used successfully in an extracorporeal filter to remove LPS from serum in plasmapheresis in an contraindicated in sepsis. Opiate antagonism (i.e. naloxone) was similarly disappointing in animal animal model;51 lipoproteins (LDL, HDL, VLDL, and chylomicrons) have been shown to block LPSmodels.61 Modulation of the cytokine cascade in sepsis has induced TNF-a secretion; indeed, hypolipoproteinaemia, especially HDL, is a common feature in sepsis, focused primarily upon those agents which sit at the head of the pathway, TNF-a and IL-1. Investigation and controlled trials of administration of parenteral lipoprotein solutions high in HDL in the septic into anti-TNF antibodies has prompted a large controlled clinical trial, the INTERSEPT study group. The postsurgical population have been promising.52 Species-specific forms of Lipid A itself are being anti-TNF antibody, BAY×1351, exhibited some efficacy in reversal of shock over placebo groups in the evaluated for the potential production of therapeutic monoclonal antibodies; lipid A from Rhodobacter study; further clinical trials are underway.62 Soluble TNF receptors, p55 and p75, which are capsulatus (E5531), for example, has shown potent anti-LPS activity in vitro, and was protective against endogenously produced in septic states and block binding of TNF to cells bearing the surface form of septic challenge in a murine model.53 Another intriguing approach uses an endotoxin-neutralizing prothe TNFR. While secretion of these agents is increased in inflammatory states, they are secreted tein produced by the Limulus polyphenus spp. horseshoe crab; a recombinant form of this product independently of serum TNF-a concentrations, indicating a constitutive, 'scavenger' role for these molecdecreased the rise in serum endotoxin and improved survival in rabbits with E. coli sepsis.54 ules.63 Other studies have shown that p55 and 75 may also enhance TNF function by stabilizing Mechanical removal of endotoxin, bacteria, and cytokine byproducts directly from blood using the active TNF isoform.64 The significance of this finding for therapeutic investigation is unclear; other haemodialysis and related techniques has been attempted, but the results so far have been disapstudies indicate that p55/75 levels can predict outcome in septic animals and increases in serum levels pointing. Although the molecular size of endotoxin and its products would not theoretically prevent 1000-fold may prevent sepsis.65 Workers have also shown that a fusion product of p55 and the Fc filtration using standard haemodialysis filters, the yield from such use has been unimpressive and the portion of IgG demonstrates improved clearance of This damage promotes coagulation overlying serum are seen in humans challenged with endodenuded subendothelial surfaces. Such microvascutoxin, suggesting a potential therapeutic role for this lar thrombosis in the setting of sepsis can rapidly product or a monoclonal antibody directed against evolve into disseminated intravascular coagulation IL-1,68 and the production of sufficient quantities of (DIC) with rapid consumption of platelets and clotting IL-1 receptor antagonists in serum will block cellular factors, resulting in a paradoxical bleeding tendency binding of IL-1 in rats and preserves microvascular in the setting of diffuse microvascular thrombosis. In integrity and function in sepsis.69 Endogenous anticombination with the already dire effects of LPS and inflammatory cytokines may also play a role; monothe cytokine cascade on endothelial integrity and clonal antibodies directed against IL-10 in endoperipheral oxygen utilization, the prognosis associtoxaemic mice causes a rapid upsurge in LPS ated with DIC can be dismal. Investigators have induction of TNF-a and IL-1 secretion, as well as initially focused upon upregulation of endogenous the pro-inflammatory cytokine, gamma interferon. 70 anticoagulant formation and, failing this, exogenous Monoclonal antibodies or other antagonists to proinanticoagulation. flammatory agents in sepsis (IL-6, IL-8) may also Apart from the standard clinical support of coaguprove of interest. 71, 72 lation in DIC with fresh frozen plasma (which has also shown beneficial endotoxin-neutralizing effects in early septic human subjects),78 laboratory isolation
Phosphodiesterase inhibitors
and purification of coagulation mediators such as antithrombin III and proteins C and S has made these A class of agents, phosphodiesterase inhibitors, agents available for the first time in forms which exhibit significant anti-inflammatory effects in sepsis avoid the infective risk inherent in prior pooled without significant detriment to endogenous antimipreparations derived from human donor plasma.79 crobial activity; these agents also preserve endothelial Apart from their better-known functions as regulators cellular function in the microvasculature via an of the coagulation cascade, these agents may also unclear mechanism (possibly maintenance of endohave direct cytokine modulatory function, and arrest thelial cell-derived nitric oxide production). The best many of the secondary sequelae of septic shock. characterized of these agents, pentoxifylline, has Activated protein C has demonstrated the ability to exhibited numerous beneficial effects in sepsis block leukocyte accumulation and vascular injury in including downregulation of TNF, IL-6, and the lungs of septic rats, presumably by inhibiting the endothelin-1 production by macrophages, improvegeneration of chemotactic factors in coagulation;80 ment of end-organ oxygen extraction from blood, protein S may function in a similar fashion. Hirudin, preservation of microvasculature blood flow, and a specific thrombin inhibitor, was coadministered reduction of the typical weight loss and muscle with tobramycin to rats with Klebsiella spp. sepsis, wasting seen in overwhelming sepsis. Improved surand led to an improvement in many DIC parameters vival in septic piglets and premature septic human such as fibrinogen and platelet count, and improved infants has been noted in controlled trials;73,74 further liver function and overall survival over that of detailed clinical testing is needed before this intricontrols with sepsis-related multi-organ failure.81 guing agent can be employed as potential therapy.
Along these same lines, the widespread intravascular A similar xanthine derivative, HWA 138, demoncoagulation typifying DIC in sepsis requires diffuse strated improved survival in septic rats over that of microvascular endothelial damage by the infecting pentoxifylline in a recent study.75 Another agent, organism or an agent produced or promoted by amrinone, has demonstrated significant benefit as an response to the organism; the body will respond to inotropic aid in hyperdynamic cardiac failure. 76 this microvascular damage through activation of the Similar to pentoxyfylline, amrinone inhibited much 'contact system' or kallikrein/kinin pathways which of the significant muscle wastage seen in sepsis by promote vasodilation and coagulation at the site. preventing TNF-induced abnormalities in skeletal Inhibitors of this system have been proposed for use muscle pyruvate dehydrogenase activity and high plasma lactate concentrations. 77 in the treatment or prevention of DIC. Agents such as C1-esterase inhibitors, monoclonal antibodies to damage and chemotactic recruitment of leukocytes. C-1 esterase inhibitors have been used, as mentioned factor XII and tissue factor, and protease inhibitors such as aprotinin may serve this purpose in combinapreviously in conjunction with arrest of the contact system, and preliminary results in humans suggest tion with other anticoagulant therapy.82-84
Also of interest in the coagulation cascade is the some ability to reverse septic hypotension.96 Production of monoclonal antibodies to complement role of platelet activating factor (PAF) in haemodynamic and microvascular compromise in sepsis, component and chemotactic factor C5a has shown inhibition in reperfusion injury in pigs with myocardand the therapeutic potential of PAF inhibitors. PAF is an inflammatory lipid involved in platelet activaial infarction, and may have similar effects in prevention of chemotaxis of leukocytes and tissue damage tion at sites of endothelial injury, neutrophil infiltration and production of oxygen radicals, and tissue in sepsis.97 Purification and production of a soluble form of the C5a receptor on the leukocyte may be damage in sepsis. 85 Terpenes, natural compounds with some limited ability to inhibit PAF activation of similarly efficacious.98 As mentioned above, endothelium modulates host response to LPS largely through neutrophils, have been evaluated, but effects of the agents are apparently transient. 86 Several synthetic the release of nitric oxide (NO). NO, while improving blood flow and leukocyte migration in localized PAF inhibitors are currently being evaluated; one, TCV-309, was shown to improve hemodynamic infection, is deleterious to microvascular integrity if not adequately controlled endogenously, and results parameters (including elevation of mean aortic pressure, cardiac output, left ventricular stroke work in significant morbidity if activated on a systemic scale. The vasodilation and hypotension incurred by index and increased urine volume) in septic beagles.87 It also suppressed the LPS-associated rise this agent induces reactive hyperdynamic cardiac function; further large-scale production of NO in TNF and the subsequent cytokine cascade in septic chimpanzees.88 Human trials are currently induces microvascular hyporesponsiveness to vasopressors such as epinephrine. The investigation and underway.
Certain prostaglandins (particularly thromboxane production of NO synthase inhibitors has also been encouraging. In rats, such an inhibitor, NG-nitro-L-A2) and bradykinin contribute to the pathophysiology of septic shock through their effects on the clotting arginine methyl ester (L-NAME), restored pulmonary vascular responsiveness 16 h following caecal ligacascade, microvascular integrity, and vasoconstriction/dilatation. Leukotrienes, on the basis of a recent tion and puncture with subsequent sepsis.99 A similar effect was noted in ovine sepsis, with restoration of study, were noncontributory to these effects. 89 Prostaglandin classes which counter these effects, vascular response to epinephrine.100 (such as PGE2 and PGI2) and cycloxygenase inhibitors (such as ibuprofen) have been studied largely Inhibition of leukocyte activity in animals and demonstrate some utility in symptomatic treatment and leukocyte inhibition in clinical Through control of the complement cascade and the contact/coagulation cascade in the microvasculature, studies, but do not in themselves prevent the onset of shock.90-92 A recent trial using a novel bradykinin many of the destructive secondary sequelae of sepsis can be avoided. In addition to the agents previously antagonist, CP-0127, or Deltibant, demonstrated statistically significant improvement in survival after a discussed, several others are in development which act at the ultimate level of microscopic tissue damage 28-day interval when administered to a small subset of patients with septic inflammatory response syndue to leukocyte migration, adhesion, transmigration, and production of proteases and oxygen radicals. drome (SIRS), or clinically-diagnosed sepsis; the remainder of the study group demonstrated no beneThe CD11/18 complex, members of the integrin family of adhesion molecules, are receptors on the fit, and the efficacy of this agent is still in question. 93 Imidazole compounds such as ketoconazole have surface of leukocytes (predominantly neutrophils) which allow adhesion to the endothelial surface and demonstrated inhibitory activity against thromboxane synthetase,94 but recent in vitro studies, while consubsequent transmigration. They are under some scrutiny as potential therapeutic agents;101 a recent firming the beneficial effects of this agent on haemodynamics in sepsis, was unable to confirm the precise study of monoclonal antibodies against CD18 (CL26) in human subjects following myocardial infarction mechanism; thromboxane synthetase activity was unchanged following administration of the imidazole demonstrated a marked decrease in neutrophil adhesion, transmigration, and reperfusion injury to the in the study.95 myocardium.102 Similarly, improvement in function of the reperfused paediatric transplanted heart followComplement, NO, and the contact system ing ischaemic cold storage was noted following administration of an antibody directed against the Inhibition of the complement cascade has been investigated, considering its central role in tissue CD11b portion of the integrin complex.103 These agents have also demonstrated antirejection effects has demonstrated activity against CNS vasodilation and pathological increases in intracranial pressures via a similar mechanism in dog lung.104 On the endothelium, molecules such as E-selectin act as in septic rats.113,114 Ascorbic acid (vitamin C) loading in septic patients has demonstrated a rapid consumpreceptors specific to leukocytes which stabilize adhesion achieved during margination. Endogenous protion of this agent over controls, presumably secondary to radical scavenging activity; however, vitamin duction of soluble E-selectin and other endotheliumderived adhesion molecules may serve both as a C has also been associated with pro-oxidant activity through its potentiation of iron-catalyzed reactions.115 serum marker of the extent of systemic endothelial damage and necrosis, but may also serve to block Thus, the clinical utility of vitamin C is unclear at this point. Vitamin E, or alpha-tocopherol, has demfurther leukocyte adhesion by binding to these cells in the circulation.105,106 Blockade of E-selectin and onstrated benefit in septic rats, with inhibition of lipid peroxidation by oxygen radicals, improvement P-selectin in burned rats using a monoclonal antibody, CY-1747, demonstrated significant inhibition in end-organ oxygen utilization, and improved survival.116 Other anti-oxidant agents, known as lazaroof leukocyte margination and sequestration in lung and liver.107 The possibility of such activity in the ids, have been shown to decrease oxygen radical lipid peroxidation in the septic rat kidney, reducing setting of sepsis-induced microvascular damage is intriguing; a recent study in septic swine used EL-246, preglomerular vasoconstriction and hypoperfusion without affecting central haemodynamics; these a monoclonal antibody with dual activity for E-and L-selectins, produced significant protection against agents may be useful for maintaining kidney function in cases of mild sepsis in the susceptible patient.117 acute lung injury by blocking neutrophil infiltration and the subsequent oxidative burst, but failed to N-acetylcysteine (NAC) decreases neutrophilinduced damage in the pulmonary vasculature of attenuate haemodynamic derangements associated with sepsis.108 Studies with similar agents are septic rats and decreases the overall incidence of alveolitis in this setting, with overall improvement in ongoing.
Blockade of neutrophil activation is of interest to oxygenation and clinical outcome.118 An intriguing class of synthetic compounds known as 'nitrones' researchers; the role of NADPH oxidase as a priming influence in neutrophil and monocyte activation and have the ability to bind covalently to large amounts of free radicals in the circulation; while their use has degranulation is a potential target for such a blockade. Two agents with the ability to block neutrophil been investigated most intensively in the area of post-ischaemic brain damage, its function as a radical activation in murine arthritis, diphenylene iodoniumchloride (DPI) and staurosporine, may have 'trap' may have obvious applications as an adjunct in the therapy of sepsis.119 The ability of nitrones to adjunctive functions in sepsis treatment. 109 In a study involving rabbits, DPI demonstrated the ability to trap NO in the microcirculation of the CNS has also been documented, and could potentially be used in inhibit lung NO generation and block hypoxiainduced vasoconstriction in the pulmonary parconjunction with the NO synthetase inhibitors mentioned previously.120 enchyma.110
Antioxidants and free radical scavenging Miscellaneous therapies
Several agents which have shown beneficial effects Following transmigration and activation, the production of oxygen radicals via the oxidative burst of the in sepsis act systemically on many different portions of the LPS inflammatory cascade, or by a poorly infiltrating neutrophil is one of the ultimate causes of tissue damage in sepsis, as noted above. Agents understood mechanism, and do not fit conveniently into the above categories. Chlorpromazine, a neurowith the ability to inhibit this burst, or its products, are being investigated for clinical use in this setting.
leptic antipsychotic with blockade of serotonin reuptake as its primary mode of function in the CNS, Other sources of oxygen radical species include activated macrophages, and various extracellular was coadministered with dexamethasone and N-acetylcysteine to septic rats, which showed amelimolecular processes such as arachidonic acid metabolism and xanthine dehydrogenase oxidation are oration of pulmonary oedema and improved survival; anxiolysis and modulation of the pituitary-adrenal noted in sepsis and ischaemia. Antioxidants such as superoxide dismutase (SOD) and catalase have been corticosteroid axis may be contributory, although its effects are difficult to separate from the other agents evaluated as prognostic serum markers in septic patients;111 patients with sepsis have low concentrain the study (NAC, as discussed above, is an oxygen radical scavenger).121 Therapy using variant steroids, tions of these and other antioxidants. SOD, in conjunction with diltiazem, was shown to decrease though controversial in the setting of overwhelming infection, has produced some interesting findings. febrile response and mortality in septic male SpragueDawley rats.112 Catalase, in conjunction with SOD, For example, while prednisone definitely downregul-ates the immune system and is contraindicated in advances in our understanding of these basic mechanisms of the systemic inflammatory response synsepsis, therapy with dehydroepiandrosterone has demonstrated an upregulatory effect in burned rats drome (SIRS) has been parlayed into the investigation and development of a multitude of agents and with gut sepsis; rats treated with DHEAS demonstrated no effect on neutrophil transmigration of gut potential therapies for sepsis based on both in vitro and in vivo animal models. Despite some encourwall, but markedly improved efficiency of PMN bacterial killing and improved time to recovery and aging results in several animal studies of sepsis ranging from mice to baboons, detailed, controlled overall survival over groups treated with prednisone and those receiving no treatment.122 Investigation human data is still largely lacking. Indeed, only a handful of the agents discussed have shown a into other hormone therapies in sepsis discovered a protective effect of the estrogen agonist estriol in sufficiently documented survival benefit in septic patients, despite this evidence in animal models. murine sepsis, largely secondary to its regulation of TNF-a, IL-1, and IL-6 production. 123 This implies that: (i) animals are not sufficient models for the unique human response to sepsis, given An interesting synthetic agent, liposomeencapsulated haemoglobin (under current consideravariances in immunity and host flora in each organism; (ii) dosages, timing of administration, and duration as a blood substitute), also has significant antiinflammatory and anti-endotoxin properties which tion of benefit are only now being defined in the animal models, and very little human data of this were unsuspected, and have been the subject of several recent animal studies. Its use in septic mice sort are available; and (iii) while antagonism documented for an agent against a specific inflammatory demonstrated modulation of the cytokine release by monocytes/macrophages, possibly by trapping LPS mechanism may imply clinical benefit, it is impossible to distill such effects from that upon the entire and presenting it for phagocytosis by the reticuloendothelial system before it can bind and activate inflammatory and immune response, and any individual antagonistic action within a single step of the cytokine release. Infusion of this agent well before LPS challenge was protective against sepsis. 124 inflammatory pathway may in fact be detrimental to the organism as a whole. For example, corticosteroThalidomide, controversial due to its significant teratogenic effects, has demonstrated the ability to block ids, currently contraindicated in sepsis due to potentiation of growth and invasion of infectious organisms, TNF-a production and improve survival in septic rats; its use in human subjects is unclear at this would misleadingly appear to benefit the patient when evaluated in the isolated context of their ability point. 125 Lastly, several new approaches involving horto circumvent much of the inflammatory cascade which complicates sepsis and ultimately causes monal and cellular manipulation at even the molecular level are under investigation. The use of death.
As research continues and more controlled clinical recombinant granulocyte-colony stimulating factor in children with sepsis is now a viable adjunct to trials are underway, we may yet encounter an agent with proven benefit in sepsis and specific action prophylaxis and care in these populations, via direct infusion in vivo, or in vitro stimulation of granulocytic against its sequelae. At present, however, the paucity of well-controlled human data forces the health-care cell lines, which are then infused to prevent infection in neutropenic individuals or combat overwhelming practitioner to focus on prevention, and early intervention with antibiotics, in the clinical settings where infection in septic patients.126-128 Gene therapy may also have something to offer in the near future; the patients are at particular risk for developing sepsis. In those patients suffering from overwhelming septic actions of endotoxin in an animal model of acute lung injury were inhibited by introducing a liposomal shock and the associated systemic inflammatory response syndrome (SIRS), a treatment protocol convector carrying the gene for prostaglandin synthase. The gene was incorporated into alveolar epithelium, sisting of antibiotics, fluid and pressor support, oxygenation and other respiratory support, and and resulted in increased production prostaglandin E2 and prostacyclin. It is speculated that genes for appropriate support of coagulation if DIC ensues (a very common complication of sepsis) is recomanti-oxidants and protease inhibitors could be similarly introduced to combat sepsis. 129, 130 mended. It is likely that, as human trials produce more reliable data, a therapeutic approach to sepsis may be devised which is both specific and global in Conclusions approach. Specific agents may be directed against single pro-inflammatory factors in sepsis, and inhibit Recent years have seen a flurry of basic science research into the dizzyingly complex pathogenesis the cascade at defined points which may be tailored to the individual patient's needs (e.g. focusing on of Gram-negative sepsis and the equally daunting inflammatory cascade left in its wake. The significant antithrombin III in septic DIC patients or on throm- 
